Neuromation Pre-sale results!

Neuromation
Neuromation
Published in
3 min readJan 1, 2018

Happy holidays from the Neuromation team!

It’s been an incredible few months for us here at Neuromation with the start of our hugely successful Neurotoken(NTK) whitelist pre-sale. We have managed to easily achieve all of our goals to date, and are confident of creating more milestones for the company as we move forward. We’ve made excellent progress with our research, product and partnerships, with 2018 already looking bright.

We are so grateful to have you onboard with us and thank you for the continued support.

Pre-Sale

We are very pleased to announce that we significantly surpassed our first goal during our whitelist presale.

45M NTK allocated! Over 30,000 ETH and 21M USD contributed!*

*numbers projected to the end of the pre-sale (Noon GMT, Jan 1st 2018)

Notice: During recess (January 1st-7th 2018) Neuromation will continue the token sale with selected partners, remaining tokens will be available in the public token sale.

Neurotoken (NTK) public sale will start January 7th and finish on the 15th of February.

Bonus structure for the sale period will be as follows:

First week + 15% in NeuroTokens (NTK)
Second week + 10% in NeuroTokens (NTK)
Third week + 5% in NeuroTokens (NTK)

Our Year

2017 really has been a phenomenal year for us at Neuromation. In just two months of our active token sale, we have achieved success on a number of fronts.

Neuromation has secured a number of strategic partnerships to help us move forward, with top companies such as Hacken- the latest and most advanced bug bounty testing service. Data sensing platform, OSA HP. And AxxonSoft, a leading developer of smart integrated security and video surveillance systems. Public announcement on this partnership will follow in the first week of sale.

Labs

Neuromation’s core team continued working on and delivering results in our labs.
Each laboratory, such as the Retail Automation Laboratory, Industrial Automation Laboratory, Pharma / Medicine / Laboratory of Biotechnology, will study a specific problem in a partnership with a category leader. As our platform evolves, we will move parts of the generation and training there, which will allow us to organically analyze parts of our vision in real-life scenarios. Stay tuned!

On the road

Chief Research Officer Sergei Nikolenko, CEO Maxim Prasolov, Chariman and Founder Constantine Goltsev, adviser Yuriy Kundin dedicated their time and efforts to spreading the vision of Neuromation all over the world. They spent plenty of time on the road over the last couple of months, performing at conferences all over the world. We were seen at the Blockchain Expo of North America, d10e in Davos, d10e in Gibraltar, d10e in Kyiv, The East West Blockchain conference in San Francisco, Ukrainian Blockchain Day and the AI & Big Data conference in Lviv. Watch the video report here.

The product and our scientists were extremely well received, even winning a number of prizes. We took out first place in Davos where the total prize pool was $250,000 USD. Third place in Gibraltar, claiming a cool $33,000 USD…and we also won a media prize at d10e in Kyiv. Plans for the next year include AI Congress in London. An effort we are extremely proud of.

Press Room

We are delighted to have received plenty of positive attention in the press over the last few months. It’s really something to see the work we have been doing, recognised by some of the most well-regarded publications, including Hacked, Wall Street Select, Ico Rating, Block Tribune, E27, Next Big Future and Yahoo Finance, ICO Daily, Digital Journal.

From all of us here at Neuromation, we would once again like to thank you for your continued support. We’ve loved having you with us on every step of this journey so far. 2017 has been an incredible ride and with the way we are progressing, 2018 is set to be even better. We wish you and your families a happy, healthy and prosperous New Year. Cheers from the team!

JOIN US ON TELEGRAM
AND OTHER SOCIAL MEDIA CHANNELS
FACEBOOK TWITTER LINKEDIN

--

--